Skip to main content

Tempest Therapeutics, Inc.

TPST
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001544227

No open-market purchases or sales by Tempest Therapeutics, Inc. insiders were filed in the last 90 days; 23 institutions reported holding it in 13F filings for Q3 2026, worth $682.2K in total; no superinvestor holds it.

Key figures

Market capClose on Nov 20, 2026
$5.74M
Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ3 2026, +3 vs. previous quarter
23
13F valueReported value at the end of Q3 2026
$682.2K
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
–
No comparable prior period
Net income, FY2025
-$26.3M
No comparable prior period
Free cash flow, FY2025
-$26.8M
No comparable prior period
Revenue, Q3 FY2026
–
No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
241.2K
Shares sold short
Change
−71.8K
−22.9% vs. previous
Days to cover
1.88
At average daily volume

Superinvestors holding TPST, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding TPST at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Tempest Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jun 23, 2026 (view filing)Mar 2491 daysLateAngel MatthewCEO and PresidentPPurchase+231.5K$2.16+$500.0KNew position231.5K afterDuplicate filing
Jun 23, 2026 (view filing)Mar 2491 daysLateAngel MatthewCEO and PresidentPPurchase+463.0K–––231.5K afterDerivative2 lots
Mar 25, 2026 (view filing)Mar 241 dayAngel MatthewCEO and PresidentPPurchase+231.5K$2.16+$500.0KNew position231.5K after
Aug 12, 2024 (view filing)8:33 PM ETAug 8-124 daysVersant Ventures IV, LLC and 8 others10% OwnerSSale−788.0K$1.23−$967.0K−79.0%209.9K after2 lots
Jul 8, 2024 (view filing)Jul 35 daysBrady Stephen RPresident and CEOPPurchase+35.0K$2.11+$73.8K+307.7%46.4K after
Jul 3, 2024 (view filing)Jul 21 dayWhiting SamuelChief Medical OfficerPPurchase+4.67K$2.13+$9.95K+95.3%9.57K after
Jul 2, 2024 (view filing)Jun 284 daysTrojanowski JustinCorporate ControllerPPurchase+7.50K$2.16+$16.2K+51.1%22.2K after
May 3, 2022 (view filing)Apr 294 daysWoiwode ThomasDirector, 10% OwnerPPurchase+2.12M$2.36+$5.00MNew position2.12M after
Jan 11, 2022 (view filing)Jan 74 daysDubensky Thomas W.PresidentPPurchase+2.00K$4.78+$9.56K+1.8%113.3K after
Jan 10, 2022 (view filing)Jan 64 daysWhiting SamuelChief Medical OfficerPPurchase+1.70K$4.80+$8.16K+845.8%1.90K after

Top 10 13F holders, Q3 2026

See all 23 holders

The largest institutional positions in Tempest Therapeutics, Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding TPST in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Versant Venture Management, LLC269,772$225.1K0.21%00.0%Unchanged
Vanguard Capital Management LLC233,888$195.1K0.00%00.0%Unchanged
Geode Capital Management, LLC74,076$61.8K0.00%−12,549−14.5%Reduced
Vanguard Fiduciary Trust Co68,908$57.5K0.00%00.0%Unchanged
BlackRock, Inc.39,068$32.6K0.00%00.0%Unchanged
UBS Group AG25,170$21.0K0.00%+19,534+346.6%Added
HRT Financial LP21,315$17.0K0.00%+21,315New
Northern Trust Corp20,136$16.8K0.00%00.0%Unchanged
Citigroup Inc15,426$12.9K0.00%+15,426New
StoneX Group Inc.13,668$11.7K0.00%+13,668New

Holders of 5% or more of TPST

See all 2 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Tempest Therapeutics, Inc..

Largest holders of TPST from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Angel Matthew13D/A37.40%5.53M shares+1.50 ppfrom 35.90%Feb 10, 20262 filingsMar 25, 2026SEC
Sabby Management, LLC13G9.90%492.2K sharesNewJan 21, 20261 filingJan 21, 2026SEC